Drugs / tolododekin alfa
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07100925 | Dec 2025 → Jun 2030 | skin squamous cell carcinoma | Ankyra Therapeutics, Inc | Withdrawn | No outcome recorded |
| Phase 1 | NCT07027514 | Oct 2025 → Jun 2027 expected | non-small cell lung carcinoma | Ankyra Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT06171750 | Jan 2024 → Apr 2027 expected | metastatic neoplasm, non-small cell lung carcinoma, skin squamous cell carcinoma, soft tissue neoplasm | Ankyra Therapeutics, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tolododekin alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06171750 ↗ |
| Known as | ANK-101 | “A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).” NCT07100925 ↗ |
| Modality | Protein / enzyme biologic | “Tolododekin alfa is a first-in-class anchored Interleukin 12 (IL-12) linked to aluminum hydroxide.” PMID 41022754 ↗ Sep 2025 |
| Route | Other | “intratumoral (IT) injection” NCT06171750 ↗ |